RPM International (RPM) to Post Q3 Earnings: What to Expect?
https://www.zacks.com/stock/news/2248462/rpm-international-rpm-to-post-q3-earnings-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_preview-2248462
Apr 01, 2024 - RPM International's (RPM) fiscal Q3 results are likely to reflect benefits from more infrastructure, reshoring and high-performance building projects amid softness in demand in DIY and specialty OEM markets.
0
Are Investors Undervaluing Post Holdings (POST) Right Now?
https://www.zacks.com/stock/news/2249720/are-investors-undervaluing-post-holdings-post-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_2-2249720
Apr 03, 2024 - Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
0
Sandstorm Gold (SAND) Posts Y/Y Preliminary Q1 Revenue Decline
https://www.zacks.com/stock/news/2252778/sandstorm-gold-sand-posts-y-y-preliminary-q1-revenue-decline?cid=CS-ZC-FT-analyst_blog|company_news_-_corporate_actions-2252778
Apr 09, 2024 - Sandstorm Gold's (SAND) preliminary revenues fall 2.7% year over year, while cash operating margins improve 7.8% in the first quarter.
0
Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?
https://www.zacks.com/stock/news/2255306/quest-diagnostics-dgx-to-post-q1-earnings-what-s-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2255306
Apr 15, 2024 - Acquisitions and partnerships with health plans are expected to drive Quest Diagnostics' (DGX) base business performance in the first quarter of 2024.
0
Align Technology (ALGN) to Post Q1 Earnings: What's in Store?
https://www.zacks.com/stock/news/2256315/align-technology-algn-to-post-q1-earnings-what-s-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2256315
Apr 16, 2024 - Align Technology's (ALGN) first-quarter 2024 performance is likely to reflect the strength of the Clear Aligner and Systems & Services businesses.
0
Alexandria (ARE) to Post Q1 Earnings: What's in the Cards?
https://www.zacks.com/stock/news/2257051/alexandria-are-to-post-q1-earnings-what-s-in-the-cards?cid=CS-ZC-FT-analyst_blog|earnings_preview-2257051
Apr 17, 2024 - While Alexandria's (ARE) Q1 earnings are likely to have benefited from the healthy demand for its high-quality life science and lab office properties, high interest expenses raise concern.
0
Bio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits?
https://www.zacks.com/stock/news/2257849/bio-rad-laboratories-bio-to-post-q1-earnings-what-awaits?cid=CS-ZC-FT-analyst_blog|earnings_preview-2257849
Apr 18, 2024 - The ongoing weakness in the biopharma end markets and tightening of sanctions against Russia is likely to have hurt Bio-Rad's (BIO) first-quarter 2024 growth.
0
Danaher (DHR) Gears Up to Post Q1 Earnings: Is a Beat Likely?
https://www.zacks.com/stock/news/2257902/danaher-dhr-gears-up-to-post-q1-earnings-is-a-beat-likely?cid=CS-ZC-FT-analyst_blog|earnings_preview-2257902
Apr 18, 2024 - Danaher's (DHR) Q1 earnings are likely to be hurt by weakness in the Biotechnology unit. Improving supply chains and strong price realization are expected to be positives.
0
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
https://www.zacks.com/stock/news/2257798/diamedica-dmac-up-as-stroke-study-dosing-begins-post-relaunch?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2257798
Apr 18, 2024 - DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.
0
CoStar Group (CSGP) to Post Q1 Earnings: What's in Store?
https://www.zacks.com/stock/news/2258714/costar-group-csgp-to-post-q1-earnings-what-s-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2258714
Apr 19, 2024 - CoStar Group's (CSGP) first-quarter 2024 top line is likely to reflect a robust portfolio of marketplaces, which includes Apartments.com, LoopNet and Homes.com.
0